{
  "$type": "site.standard.document",
  "bskyPostRef": {
    "cid": "bafyreigfbnuqfad52r2c5mf7h732f6ehmigxiqcesjc7u47ah4bgz6ylnq",
    "uri": "at://did:plc:ox2kiwcr2xmn32p25g472pp7/app.bsky.feed.post/3mmkmyhcauxl2"
  },
  "coverImage": {
    "$type": "blob",
    "ref": {
      "$link": "bafkreigwaiqjf7nahwke5aswbihiyc622zjaplyzjnfmadmwxya5z65aim"
    },
    "mimeType": "image/webp",
    "size": 78844
  },
  "path": "/releases/2026/05/260522023134.htm",
  "publishedAt": "2026-05-23T09:23:30.000Z",
  "site": "https://www.sciencedaily.com",
  "textContent": "A new analysis is raising concerns about Wegovy, the blockbuster weight-loss drug, after researchers found it may carry the highest risk of a rare “eye stroke” that can cause sudden vision loss. The study, based on millions of FDA side-effect reports, found the risk signal was nearly five times stronger for Wegovy than for Ozempic, despite both containing semaglutide.",
  "title": "Wegovy linked to rare “eye stroke” that can cause sudden blindness"
}